IIM
CYTK icon

INTECH Investment Management’s Cytokinetics CYTK Stock Holding History

INTECH Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.97M Buy
58,348
+5,000
+9% +$359K 0.05% 358
2026
Q1 		$3.52M Buy
53,348
+3,914
+8% +$249K 0.03% 452
2025
Q4 		$3.14M Buy
49,434
+10,775
+28% +$670K 0.03% 533
2025
Q3 		$2.12M Sell
38,659
-14,564
-27% -$600K 0.02% 750
2025
Q2 		$1.76M Sell
53,223
-14,038
-21% -$488K 0.02% 842
2025
Q1 		$2.7M Buy
67,261
+16,988
+34% +$781K 0.03% 596
2024
Q4 		$2.36M Buy
50,273
+17,602
+54% +$914K 0.02% 615
2024
Q3 		$1.73M Buy
+32,671
New +$1.82M 0.02% 538

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

INTECH Investment Management's CYTK Position: Q2 2026 in Review

INTECH Investment Management increased its Cytokinetics (CYTK) stake by 9.4% in Q2 2026, buying an estimated $359K and bringing the position to 58,348 shares worth $4.97M. The position accounts for 0.05% of the portfolio, ranked #358.

INTECH Investment Management first reported a position in CYTK in Q3 2024 and has held it in 8 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • INTECH Investment Management held 58,348 shares of Cytokinetics worth $4.97M as of Q2 2026.
  • INTECH Investment Management bought 5,000 Cytokinetics shares in Q2 2026, an estimated $359K.
  • Cytokinetics made up 0.05% of INTECH Investment Management's portfolio in Q2 2026, its #358 holding.
  • INTECH Investment Management first reported a position in Cytokinetics in Q3 2024 and has held it in 8 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.